You don't go to settlement unless the judge thinks you have a case. Because the only reason you go to settlement is to avoid a court date where you might lose. Day in court will come if APPL doesn't settle.
Having been I sales management all my life this is the ratio you expect when running a team.
The reduction of sales staff was appropriate and should result in stronger sales as AMRN locked in the 20% and got rid of non perfomers. Lower costs from this reduction should start to build momentum in the bottom line over the next several quarters.
I think this is the line your looking for. It is at that bottom of the ruling as an adjunct to the last paragraph of the ruling Doesn't this interpretation mean that the supposed negative ruling doesn't include devices including microcontrollers? So this now goes to a jury?
I make clear that this construction does not read out embodiments including microcontrollers
Case 1:11-cv-00765-RGA Document 62 Filed 02/19/14 Page 7 of 7 PageID #: 5440
so they were not apart of the Samsung deal. To me I extrapolate that our Erickson patents have value to Samsung too so we may see a deal to cover all Erickson patents including ours. Considering that Erickson won the battle we are in a very good family of patents. We need a couple more 30 million dollar deals like with Microsoft. At 7 million a quarter expense we have two years worth of cash to operate but one deal could extend that to 5 years or more. Being able to last it out means allot to those that owe us. I say we go up from here when you put everything together.
We should be back up to $500 mill in the bank to fund all of 102. I can tell you right now results must be very positive with 102. This money will be used to move forward. This is not a big dilution
In order to balance the offering out with dilution, you can bet on very good news soon on certain elements of the pipeline that will have this sailing past $15. So all of you that sell will miss that boat. Don't sell, good news is coming anyday.
Irish biopharmaceutical firm Amarin Corp is up sharply Wednesday ahead of an expected FDA
decision on its drug candidate for fatty liver disese.